SAB Biotherapeutics, Inc. cash flow to debt ratio of -752.44% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

SAB Biotherapeutics, Inc.'s free cash flow has decreased 32.00% from $-34.63M last year to $-45.71M, signaling decreasing performance

SAB Biotherapeutics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

SAB Biotherapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.18 last year to 0.02 today, signaling strengthened financials

SAB Biotherapeutics, Inc. has a net cash position, so leverage is healthy.

SAB Biotherapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

SAB Biotherapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -2.58K% to 0.00%, signaling increasing performance

SAB Biotherapeutics, Inc.'s short-term assets of $101.05M exceed its short-term liabilities of $10.68M

SAB Biotherapeutics, Inc.'s return on assets of -5.36% is lower than the 5.00% threshold, indicating inefficient asset utilization

SAB Biotherapeutics, Inc.'s return on equity of -6.74%, is lower than 15.00%, indicating bad performance

SAB Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

SAB Biotherapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

SAB Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

SAB Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

SAB Biotherapeutics, Inc.'s yearly earnings has increased -138.92% since last year from $-34.11M to $13.27M, signaling increasing performance

SAB Biotherapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $1.32M to $0.00, signaling decreasing performance

ROIC -31.62% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

SAB Biotherapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

SAB Biotherapeutics, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

SAB Biotherapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

SAB Biotherapeutics, Inc. has insufficient data to evaluate this check.

SAB Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

SAB Biotherapeutics, Inc. is undervalued relative to its fair value price of 12.64 based on EBITDA multiple model

SAB Biotherapeutics, Inc. has an EV/EBITDA ratio of 15.26x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

SAB Biotherapeutics, Inc. has insufficient data to evaluate this check.

SAB Biotherapeutics, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

SAB Biotherapeutics, Inc. has a price-to-book ratio of 1.40x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

SAB Biotherapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue